Allena Pharmaceuticals, Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending March 31, 2022 was $249 Thousand (a -0.4% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses increased by 139.42%
  • Annual Non-operating Interest Expenses for 2019 was $270 Thousand (a -53.04% decrease from previous year)
  • Twelve month Non-operating Interest Expenses ending March 31, 2022 was $838 Thousand
Trailing Non-operating Interest Expenses for the last four month:
31 Mar '22
$838 Thousand
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of Allena Pharmaceuticals, Inc.

Most recent Non-operating Interest Expensesof ALNA including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.25
2021 $0.25 $0.24
2020 $0.1
2019 $0.27
2018 $0.58

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.